

Technology Advisory Committee B Interests Register

Topic [ID2692] Bimekizumab for treating moderate to severe plaque psoriasis

Publication Date: 01/09/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Laura Bojke	Committee member	Direct financial	Laura has undertaken consultancy work for Amgen, via a consultancy. This was in a different indication and a different product.		15/06/2021		It was agreed that this declaration did not prevent Dr Bojke from participating in this section of the meeting.
Dr James Fotheringham	Committee member	Direct financial	He received consultancy and speaker fees from Novartis for promotional activity around a risk prediction tool they are using for a trial currently underway in kidney transplantation. Novartis is a comparator company for this topic.		14/06/2021		It was agreed that this declaration did not prevent Dr Fotheringham from participating in this section of the meeting.
Dr Nicholas Latimer	Committee member	Non-financial professional and personal	He is a member of the SchARR team working on an ongoing consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-		14/06/2021		It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.

			receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis is a comparator company for this topic.				
--	--	--	---	--	--	--	--